BENGALURU: Biocon has partnered with DKSH to expand its generic drugs business in Singapore and Thailand.
The Indian biotech major said it has signed a pact through Biocon Pharma, a subsidiary, with DKSH Business Unit Healthcare to sell and distribute seven generic formulations in Singapore and Thailand.
As a part of the pact, DKSH will gain an exclusive license to register and commercialize these seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology and immunology, which will be sold under Biocon’s brand in these key Asian markets.
“This collaboration will enable us to address the growing patient needs for affordable access to high-quality generics for chronic diseases and expand our commercial footprint in this region. Our generic formulations pipeline comprises difficult-to-make, complex molecules and leverages our strong track record of quality and reliability of supplies to our patients and customers,” said Siddharth Mittal, chief executive officer and managing director, Biocon.
DKSH will manage marketing and sales as well as logistics for Biocon Pharma, helping drive sales growth through its capabilities and strengths in the medical and pharmacy channels.
This development is in line with Biocon’s strategy for expansion of its generic formulations business through licensing of its drug products in multiple markets, said Biocon in a press release.